Analyst: This Drug Stock Could Surge 60%

RCKT shares have nearly doubled in 2018

Jul 10, 2018 at 2:13 PM
facebook twitter linkedin


The shares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) -- which specializes in rare disease therapies -- are higher today, thanks to some bullish analyst attention. Specifically, William Blair initiated coverage of RCKT stock with an "outperform" rating and a fair-value target of $32 -- representing expected upside of 63% from the security's close of $19.68 on Monday. The analyst wrote that Rocket Pharma has "ambitious goals for a relatively young company, [but] execution on this strategy could unlock significant value creation for shareholders."

Rocket Pharmaceuticals stock was last seen 3.9% higher to trade at $20.45. The company merged with Inotek Pharmaceuticals in early January, and has nearly doubled year-to-date, with pullbacks contained by its 80-day moving average. Further, RCKT stock today is set to end atop its 20-day moving average for the first time since June 20, when the shares were still lingering near annual-high territory.

RCKT stock chart july 10

An unwinding of short interest could also propel RCKT higher. Short interest jumped 52.2% during the past two reporting periods, and now accounts for more than 2 million Rocket Pharmaceuticals shares. At the security's average pace of trading, it would take more than six sessions to repurchase these pessimistic positions -- ample fuel for a short squeeze.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners